Redhill Biopharma Ltd ADR(RDHL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:53 PM ET (Korea 10/28 05:53)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 11.09% | Shs Outstand | 8.9M | Perf Week | -11.67% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -96.65% | Shs Float | 7.9M | Perf Month | -11.36% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 3.48% | Short Float | 1.62% | Perf Quarter | -34.37% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 0.32% | Short Ratio | 0.06 | Perf Half Y | -56.91% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.13M | Perf YTD | -56.5% |
| Book/sh | -0.18 | P/C | 0.77 | EPS past 3/5Y | 95.56% 86.32% | ROE | - | 52W High | -73.17% ($1.67) | Perf Year | -71.46% |
| Cash/sh | 0.58 | P/FCF | - | Sales past 3/5Y | -83.27% -66.14% | ROIC | - | 52W Low | 14.87% ($0.39) | Perf 3Y | -96.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.65% | Gross Margin | - | Volatility(W/M) | 10.52% 10.27% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 102.33% | Profit Margin | - | RSI (14) | 41 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.34 | Sales Q/Q | -90.2% | SMA20 | -7.75% ($0.49) | Beta | 4.92 | Target Price | $7.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/4/27 | SMA50 | -21.22% ($0.57) | Rel Volume | 0.05 | Prev Close | $0.42 |
| Employees | 13 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -45.57% ($0.83) | Avg Volume(3M) | 2.04M | Price | $0.45 |
| IPO | 2013/1/7 | Option/Short | No/Yes | Trades | 102 | Volume | 109,490 | Change | 7.74% |
💊 RedHill Biopharma () is a specialty pharmaceutical company headquartered in Israel that focuses on gastrointestinal, infectious disease, and oncology therapeutics. Its core revenue driver is Talicia, a treatment for Helicobacter pylori, and the company is working to reduce losses and improve its fundamentals through a co-promotion agreement with Cumberland () in 2025 and progress in its late-stage clinical pipeline.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded less than usual. That is 5% of its average volume.
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.5%.
Tap to view numbers
It ranks #78 of 83 in the industry
Based on market cap of $4M.
SNOA#74 Sonoma Pharmaceuticals Inc $6M PER - 
GELS#75 Gelteq Ltd $5M PER - 
APUS#76 Apimeds Pharmaceuticals US Inc $5M PER - 
YCBD#77 cbdMD Inc $4M PER - RDHL#78 Redhill Biopharma Ltd ADR $4M PER - 
FAQ
What kind of company is RDHL?
RDHL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RDHL?
The market cap of RDHL is approximately $4M, ranking 5,670 within its sector.
What is the 52-week high and low for RDHL?
RDHL has recorded a 52-week high of $1.67 and a low of $0.39.
